Bolstering Public Health Preparedness by Investing in Post-Market Incentives for Novel Antibiotics
Drug-resistant infections and antimicrobial resistance (AMR) threaten global public health, and access to innovative, novel antibiotics is critical to prepare for future health emergencies.
On October 23rd, 2023, Duke-Margolis published “Bolstering Public Health Preparedness by Investing in Post-Market Incentives for Novel Antibiotics” to describe opportunities for policymakers to establish pull incentives for novel antibiotics that advance public health preparedness and the bioindustrial base.
- Investments in post-market incentives for novel antibiotics represent investments in public health preparedness.
- Until proposals to prevent viral pandemics and bolster public health preparedness are aligned with related efforts to combat antibiotic resistant bacteria, the United States will remain at risk.
- Policymakers can support pharmaceutical manufacturing and supply chains, surveillance systems, post-market evidence development infrastructure, and diagnostic capabilities in a manner that reduces post-market costs for the smaller novel antibiotic developers who conduct the majority of current antibiotic research and development.
Funding Acknowledgement & Disclaimer
The policy research that informed this paper was supported by the Wellcome Trust. The opinions and conclusions expressed or implied are those of the authors and do not necessarily represent the official views of, nor an endorsement, by the Wellcome Trust.